Traumatic brain injury biomarkers: from pipeline to diagnostic assay development.
In recent years, the term proteomics is often mentioned together with biomarker discovery, as proteomic studies have the capability of identifying unique and unobvious protein biomarkers from tissues or biofluids derived from animal models or human clinical samples inflicted with various diseases. Proteomics has yielded hundreds of potential biomarker candidates. However, biomarker discovery is only the beginning of a long road for generating a validated, clinically relevant, and FDA-approved biomarker assay. Many technical, financial, legal, and regulatory hurdles have to be overcome before the components can be commercially produced (1, 2). This chapter outlines in a condensed version the steps to successfully develop clinically acceptable biomarkers, given the marker of choice withstands the rigor of developmental challenges along the road.
Oli
Monika W
MW
Research and Development Department, Banyan Biomarkers Inc., Alachua, FL, USA. moli@ufl.edu
Hayes
Ronald L
RL
Robinson
Gillian
G
Wang
Kevin K W
KK
D000818:Animals; D001681:Biological Assay / Q000379:methods; D015415:Biomarkers / Q000378:metabolism*; D001930:Brain Injuries / Q000175:diagnosis / Q000378:metabolism; D002986:Clinical Trials as Topic; D018795:Device Approval; D006801:Humans; D040901:Proteomics / Q000379:methods; D015203:Reproducibility of Results
D015415:Biomarkers